Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) saw a downside of -5.00% to close Friday at $21.86 after subtracting -$1.15 on the day. The 5-day average trading volume is 390,120 shares of the company’s common stock. It has gained $26.00 in the past week. An average of 688,510 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 469,876.
RXRX’s 1-month performance is -11.78% or -$2.92 on its low of $20.66 reached on 10/01/21. The company’s shares have touched a 52-week low of $17.80 and high of $42.81. YTD, RXRX has lost -30.16%. However, the current price is down -48.94%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Recursion Pharmaceuticals Inc. (RXRX) has a trailing price-to-earnings (P/E) ratio of 33.74 for the broader industry and 32.48 for the sector, meaning that investors are optimistic about the stock’s future prospects. RXRX stock has a beta of 0.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 419.47 while the price-to-book (PB) in the most recent quarter is 4.70.
Recursion Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 21.90, with the current ratio over the same period at 21.90 meaning that RXRX stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.01, while the total debt to equity was 0.02The trailing 12-month EBITDA margin is -2023.55%. The firm’s gross profit as reported stood at $88.58 million against revenue of $3.96 million.
The effectiveness of a company’s management is also important for investors when it comes to determining the potential profitability of the investment. Return on investment over the past year is 44.10%. In comparison, the average ROE for the broader industry over the past year is -36.91.
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected RXRX to announce -$0.23 per share in earnings in its latest quarter, but it posted -$0.31, representing a -34.80% surprise. EBITDA for the quarter stood at more than -$38.6 million. RXRX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 55.88 million, with total debt at $15.48 million. Shareholders hold equity totaling $168.48 million
Let’s look briefly at Recursion Pharmaceuticals Inc. (RXRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 01 October was 34.56% to suggest the stock is trending Neutral, with historical volatility in this time period at 50.19%.
The stock’s 5-day moving average is $22.92, reflecting a -10.85% or -$2.66 change from its current price. RXRX is currently trading -17.94% above its 20-day SMA, -3.53% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -39.26%.
Stochastic %K and %D was 16.86% and 15.53% and the average true range (ATR) pointed at 2.26. The RSI (14) points at 38.68%, while the 14-day stochastic is at 16.81% with the period’s ATR at 2.27. The stock’s 9-day MACD Oscillator is pointing at -1.40 and -1.99 on the 14-day charts.
In the most recent analyst report for Recursion Pharmaceuticals Inc. (NASDAQ: RXRX), Berenberg launched coverage with a Buy rating. Analysts offering their rating for RXRX stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate RXRX as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 3 have offered a “buy” rating.
What is RXRX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $30.00 and a high of $37.00, with their median price target at $34.00. Looking at these predictions, the average price target given by analysts is for Recursion Pharmaceuticals Inc. (RXRX) stock is $33.60.